While studying the copy number variation analysis (CNV) of cytochromes and GSTs to predict efficacy of TKI in CML the researchers proposed that GSTM1 may not be a specific marker to prognose treatment outcome but GSTT1 may be associated with CML [3]. This evidence concerns the gene HPGDS and chronic myelogenous leukemia, BCR-ABL1 positive.